Anti-p95 NBS1 (phospho S343) antibody
| Name | Anti-p95 NBS1 (phospho S343) antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab47272 |
| Prices | $392.00 |
| Sizes | 100 µg |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | WB ELISA |
| Species Reactivities | Human |
| Antigen | Synthesized phosphopeptide derived from human p95/NBS1 around the phosphorylation site of serine 343 (S-L-SP-Q-G) |
| Description | Rabbit Polyclonal |
| Gene | NBN |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
All lanes : Anti-p95 NBS1 (phospho S343) antibody (ab47272) at 1/500 dilutionLane 1 : 5-30ug Jurkat cell extract, treated with immunogenic peptide.Lane 2 : 5-30ug Jurkat cell extract, untreated.SecondaryAlkaline Phosphatase Goat Anti IgG (H+L)
All lanes : Anti-p95 NBS1 (phospho S343) antibody (ab47272) at 1/500 dilutionLane 1 : Unirradiated Human lymphoblastoid cell lines from normal individual - Whole cell lysateLane 2 : Irradiated Human lymphoblastoid cell lines from normal individual - Whole cell lysateLane 3 : Unirradiated Human lymphoblastoid cell lines from classical A-T patient (no ATM kinase expressed) - Whole cell lysateLane 4 : Irradiated Human lymphoblastoid cell lines from classical A-T patient (no ATM kinase expressed) - Whole cell lysateLysates/proteins at 50 µg per lane.SecondaryAn HRP-conjugated Goat polyclonal to rabbit IgG at 1/3000 dilution
Product References
Direct activation of ATM by resveratrol under oxidizing conditions. - Direct activation of ATM by resveratrol under oxidizing conditions.
Lee JH, Guo Z, Myler LR, Zheng S, Paull TT. PLoS One. 2014 Jun 16;9(6):e97969.
Requirement for NBS1 in the S phase checkpoint response to DNA methylation - Requirement for NBS1 in the S phase checkpoint response to DNA methylation
Horton JK, Stefanick DF, Zeng JY, Carrozza MJ, Wilson SH. DNA Repair (Amst). 2011 Feb 7;10(2):225-34.
Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial - Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial
Reiman A, Srinivasan V, Barone G, Last JI, Wootton LL, Davies EG, Verhagen MM, Willemsen MA, Weemaes CM, Byrd PJ, Izatt L, Easton DF, Thompson DJ, Taylor AM. Br J Cancer. 2011 Aug 9;105(4):586-91.
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid - The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T. Blood. 2010 Nov 25;116(22):4578-87.